However, there is growing evidence that multiple lymphocyte subsets are involved in the complex and heterogeneous pathogenesis of MS, ranging from B cells, NK cells, and CD8+ T cells, demonstrating that these are promising targets for immunotherapy in MS (van Langelaar et al., 2020). This evidence concerns the gene CD8A and myeloid sarcoma.